Rain Therapeutics GAAP EPS of -$0.68 misses by $0.06
- Rain Therapeutics press release (NASDAQ:RAIN): Q4 GAAP EPS of -$0.68 misses by $0.06.
- Q4 Net loss $51.4M.
- As of December 31, 2021, Rain had $140.2 million in cash, cash equivalents and short-term investments. Rain anticipates that its year-end cash position will provide runway into the first half of 2024, including completion of all its ongoing and planned clinical trials with an ample cash cushion for the Phase 3 MANTRA trial in liposarcoma.